Santen Pharmaceutical Co., Ltd. Logo

Santen Pharmaceutical Co., Ltd.

SNPHF

(1.2)
Stock Price

10,15 USD

7.65% ROA

8.82% ROE

22.07x PER

Market Cap.

584.864.383.228,14 USD

0% DER

2.06% Yield

8.83% NPM

Santen Pharmaceutical Co., Ltd. Stock Analysis

Santen Pharmaceutical Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Santen Pharmaceutical Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.51x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 Dividend

Investors can rely on the company's consistent dividend payments over the past three years, offering a steady stream of returns.

5 ROE

Negative ROE (-4.79%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-4.58%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

9 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-6.138) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Santen Pharmaceutical Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Santen Pharmaceutical Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Sell
4 Stoch RSI Sell

Santen Pharmaceutical Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Santen Pharmaceutical Co., Ltd. Revenue
Year Revenue Growth
2005 92.696.000.000
2006 98.397.000.000 5.79%
2007 100.485.000.000 2.08%
2008 103.394.000.000 2.81%
2009 101.618.000.000 -1.75%
2010 110.594.000.000 8.12%
2011 110.812.000.000 0.2%
2012 114.416.000.000 3.15%
2013 119.066.000.000 3.91%
2014 148.663.000.000 19.91%
2015 161.831.000.000 8.14%
2016 195.291.000.000 17.13%
2017 199.096.000.000 1.91%
2018 224.942.000.000 11.49%
2019 234.026.000.000 3.88%
2020 241.555.000.000 3.12%
2021 249.605.000.000 3.23%
2022 266.257.000.000 6.25%
2023 293.668.000.000 9.33%
2023 279.037.000.000 -5.24%
2024 301.965.000.000 7.59%
2025 299.084.000.000 -0.96%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Santen Pharmaceutical Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 16.719.000.000 100%
2014 16.862.000.000 0.85%
2015 17.477.000.000 3.52%
2016 19.990.000.000 12.57%
2017 22.786.000.000 12.27%
2018 24.398.000.000 6.61%
2019 23.759.000.000 -2.69%
2020 23.341.000.000 -1.79%
2021 24.112.000.000 3.2%
2022 26.377.000.000 8.59%
2023 24.636.000.000 -7.07%
2023 28.297.000.000 12.94%
2024 24.703.000.000 -14.55%
2025 22.016.000.000 -12.2%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Santen Pharmaceutical Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 41.642.000.000 100%
2015 48.893.000.000 14.83%
2016 59.406.000.000 17.7%
2017 62.193.000.000 4.48%
2018 68.788.000.000 9.59%
2019 71.273.000.000 3.49%
2020 73.360.000.000 2.84%
2021 79.554.000.000 7.79%
2022 84.499.000.000 5.85%
2023 88.432.000.000 4.45%
2023 96.257.000.000 8.13%
2024 91.529.000.000 -5.17%
2025 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Santen Pharmaceutical Co., Ltd. EBITDA
Year EBITDA Growth
2005 23.769.000.000
2006 26.288.000.000 9.58%
2007 25.623.000.000 -2.6%
2008 25.420.000.000 -0.8%
2009 20.207.000.000 -25.8%
2010 32.876.000.000 38.54%
2011 34.494.000.000 4.69%
2012 30.751.000.000 -12.17%
2013 28.897.000.000 -6.42%
2014 32.018.000.000 9.75%
2015 43.100.000.000 25.71%
2016 90.300.000.000 52.27%
2017 43.269.000.000 -108.69%
2018 50.591.000.000 14.47%
2019 56.967.000.000 11.19%
2020 51.057.000.000 -11.58%
2021 30.674.000.000 -66.45%
2022 53.880.000.000 43.07%
2023 66.380.000.000 18.83%
2023 12.949.000.000 -412.63%
2024 70.081.000.000 81.52%
2025 71.452.000.000 1.92%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Santen Pharmaceutical Co., Ltd. Gross Profit
Year Gross Profit Growth
2005 58.987.000.000
2006 63.863.000.000 7.64%
2007 65.002.000.000 1.75%
2008 66.881.000.000 2.81%
2009 65.671.000.000 -1.84%
2010 75.884.000.000 13.46%
2011 76.376.000.000 0.64%
2012 79.031.000.000 3.36%
2013 77.565.000.000 -1.89%
2014 90.559.000.000 14.35%
2015 105.458.000.000 14.13%
2016 122.462.000.000 13.89%
2017 124.130.000.000 1.34%
2018 138.564.000.000 10.42%
2019 143.262.000.000 3.28%
2020 146.724.000.000 2.36%
2021 151.384.000.000 3.08%
2022 156.586.000.000 3.32%
2023 175.944.000.000 11%
2023 166.087.000.000 -5.93%
2024 163.876.000.000 -1.35%
2025 171.064.000.000 4.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Santen Pharmaceutical Co., Ltd. Net Profit
Year Net Profit Growth
2005 11.022.000.000
2006 13.022.000.000 15.36%
2007 13.147.000.000 0.95%
2008 12.650.000.000 -3.93%
2009 10.123.000.000 -24.96%
2010 18.722.000.000 45.93%
2011 21.333.000.000 12.24%
2012 17.160.000.000 -24.32%
2013 16.520.000.000 -3.87%
2014 19.718.000.000 16.22%
2015 24.032.000.000 17.95%
2016 53.373.000.000 54.97%
2017 21.724.000.000 -145.69%
2018 35.261.000.000 38.39%
2019 31.954.000.000 -10.35%
2020 23.618.000.000 -35.3%
2021 6.830.000.000 -245.8%
2022 27.218.000.000 74.91%
2023 35.464.000.000 23.25%
2023 -14.948.000.000 337.25%
2024 26.642.000.000 156.11%
2025 42.532.000.000 37.36%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Santen Pharmaceutical Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 25
2006 30 16.67%
2007 30 0%
2008 29 -3.45%
2009 24 -26.09%
2010 44 47.73%
2011 50 10.2%
2012 39 -25.64%
2013 39 0%
2014 48 17.02%
2015 58 18.97%
2016 129 54.69%
2017 53 -146.15%
2018 87 39.53%
2019 79 -10.26%
2020 59 -32.2%
2021 17 -247.06%
2022 68 75%
2023 98 30.61%
2023 -39 357.89%
2024 73 152.78%
2025 118 38.98%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Santen Pharmaceutical Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2005 1.713.000.000
2006 18.772.000.000 90.87%
2007 11.404.000.000 -64.61%
2008 15.468.000.000 26.27%
2009 11.849.000.000 -30.54%
2010 26.110.000.000 54.62%
2011 17.769.000.000 -46.94%
2012 21.483.000.000 17.29%
2013 6.334.000.000 -239.17%
2014 20.079.000.000 68.45%
2015 -41.054.000.000 148.91%
2016 13.433.000.000 405.62%
2017 1.343.000.000 -900.22%
2018 32.906.000.000 95.92%
2019 24.561.000.000 -33.98%
2020 30.719.000.000 20.05%
2021 15.004.000.000 -104.74%
2022 10.202.000.000 -47.07%
2023 12.559.000.000 18.77%
2023 22.930.000.000 45.23%
2024 61.962.000.000 62.99%
2025 11.564.000.000 -435.82%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Santen Pharmaceutical Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2005 6.619.000.000
2006 20.878.000.000 68.3%
2007 14.959.000.000 -39.57%
2008 15.468.000.000 3.29%
2009 11.849.000.000 -30.54%
2010 26.110.000.000 54.62%
2011 17.769.000.000 -46.94%
2012 21.483.000.000 17.29%
2013 9.942.000.000 -116.08%
2014 25.958.000.000 61.7%
2015 25.386.000.000 -2.25%
2016 22.525.000.000 -12.7%
2017 10.843.000.000 -107.74%
2018 42.843.000.000 74.69%
2019 32.894.000.000 -30.25%
2020 39.947.000.000 17.66%
2021 38.808.000.000 -2.93%
2022 46.043.000.000 15.71%
2023 37.147.000.000 -23.95%
2023 25.188.000.000 -47.48%
2024 72.649.000.000 65.33%
2025 12.139.000.000 -498.48%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Santen Pharmaceutical Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2005 4.906.000.000
2006 2.106.000.000 -132.95%
2007 3.555.000.000 40.76%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 3.608.000.000 100%
2014 5.879.000.000 38.63%
2015 66.440.000.000 91.15%
2016 9.092.000.000 -630.75%
2017 9.500.000.000 4.29%
2018 9.937.000.000 4.4%
2019 8.333.000.000 -19.25%
2020 9.228.000.000 9.7%
2021 23.804.000.000 61.23%
2022 35.841.000.000 33.58%
2023 24.588.000.000 -45.77%
2023 2.258.000.000 -988.93%
2024 10.687.000.000 78.87%
2025 575.000.000 -1758.61%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Santen Pharmaceutical Co., Ltd. Equity
Year Equity Growth
2005 108.239.000.000
2006 118.637.000.000 8.76%
2007 128.645.000.000 7.78%
2008 127.118.000.000 -1.2%
2009 125.368.000.000 -1.4%
2010 137.603.000.000 8.89%
2011 156.404.000.000 12.02%
2012 164.861.000.000 5.13%
2013 165.131.000.000 0.16%
2014 181.208.000.000 8.87%
2015 211.779.000.000 14.44%
2016 260.009.000.000 18.55%
2017 253.884.000.000 -2.41%
2018 287.557.000.000 11.71%
2019 292.572.000.000 1.71%
2020 302.560.000.000 3.3%
2021 307.050.000.000 1.46%
2022 336.843.000.000 8.84%
2023 293.296.000.000 -14.85%
2023 306.455.000.000 4.29%
2024 305.369.000.000 -0.36%
2025 305.937.000.000 0.19%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Santen Pharmaceutical Co., Ltd. Assets
Year Assets Growth
2005 139.979.000.000
2006 150.458.000.000 6.96%
2007 159.098.000.000 5.43%
2008 156.547.000.000 -1.63%
2009 151.012.000.000 -3.67%
2010 166.878.000.000 9.51%
2011 184.801.000.000 9.7%
2012 198.801.000.000 7.04%
2013 199.639.000.000 0.42%
2014 231.104.000.000 13.62%
2015 304.200.000.000 24.03%
2016 355.399.000.000 14.41%
2017 322.778.000.000 -10.11%
2018 388.463.000.000 16.91%
2019 391.186.000.000 0.7%
2020 408.768.000.000 4.3%
2021 402.353.000.000 -1.59%
2022 459.976.000.000 12.53%
2023 421.179.000.000 -9.21%
2023 426.984.000.000 1.36%
2024 435.699.000.000 2%
2025 434.156.000.000 -0.36%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Santen Pharmaceutical Co., Ltd. Liabilities
Year Liabilities Growth
2005 31.740.000.000
2006 31.821.000.000 0.25%
2007 30.453.000.000 -4.49%
2008 29.429.000.000 -3.48%
2009 25.644.000.000 -14.76%
2010 29.275.000.000 12.4%
2011 28.397.000.000 -3.09%
2012 33.940.000.000 16.33%
2013 34.508.000.000 1.65%
2014 49.896.000.000 30.84%
2015 92.421.000.000 46.01%
2016 95.390.000.000 3.11%
2017 68.894.000.000 -38.46%
2018 100.906.000.000 31.72%
2019 98.614.000.000 -2.32%
2020 106.208.000.000 7.15%
2021 95.303.000.000 -11.44%
2022 123.132.000.000 22.6%
2023 127.882.000.000 3.71%
2023 120.530.000.000 -6.1%
2024 130.330.000.000 7.52%
2025 89.905.000.000 -44.96%

Santen Pharmaceutical Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
844.37
Net Income per Share
74.52
Price to Earning Ratio
22.07x
Price To Sales Ratio
1.92x
POCF Ratio
7.21
PFCF Ratio
7.91
Price to Book Ratio
1.93
EV to Sales
1.63
EV Over EBITDA
7.62
EV to Operating CashFlow
6.02
EV to FreeCashFlow
6.7
Earnings Yield
0.05
FreeCashFlow Yield
0.13
Market Cap
584,86 Bil.
Enterprise Value
495,12 Bil.
Graham Number
1194.42
Graham NetNet
244.4

Income Statement Metrics

Net Income per Share
74.52
Income Quality
3.07
ROE
0.09
Return On Assets
0.06
Return On Capital Employed
0.14
Net Income per EBT
0.77
EBT Per Ebit
0.74
Ebit per Revenue
0.16
Effective Tax Rate
0.1

Margins

Sales, General, & Administrative to Revenue
0.23
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.58
Operating Profit Margin
0.16
Pretax Profit Margin
0.12
Net Profit Margin
0.09

Dividends

Dividend Yield
0.02
Dividend Yield %
2.06
Payout Ratio
0.45
Dividend Per Share
0.23

Operating Metrics

Operating Cashflow per Share
228.18
Free CashFlow per Share
205.08
Capex to Operating CashFlow
0.1
Capex to Revenue
0.03
Capex to Depreciation
0.44
Return on Invested Capital
0.14
Return on Tangible Assets
0.08
Days Sales Outstanding
100.29
Days Payables Outstanding
130.5
Days of Inventory on Hand
146.05
Receivables Turnover
3.64
Payables Turnover
2.8
Inventory Turnover
2.5
Capex per Share
23.1

Balance Sheet

Cash per Share
248,98
Book Value per Share
955,08
Tangible Book Value per Share
724.2
Shareholders Equity per Share
850.86
Interest Debt per Share
9.1
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-1.38
Current Ratio
2.6
Tangible Asset Value
261,03 Bil.
Net Current Asset Value
143,97 Bil.
Invested Capital
299404000000
Working Capital
143,97 Bil.
Intangibles to Total Assets
0.19
Average Receivables
87,08 Bil.
Average Payables
34,84 Bil.
Average Inventory
47126000000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Santen Pharmaceutical Co., Ltd. Dividends
Year Dividends Growth
2011 50
2012 50 0%
2013 100 50%
2014 1 0%
2015 3 100%
2016 13 84.62%
2017 0 0%
2018 0 0%
2019 13 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%
2025 0 0%

Santen Pharmaceutical Co., Ltd. Profile

About Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

CEO
Mr. Takeshi Ito
Employee
3.744
Address
Grand Front Osaka Tower A
Osaka, 530-8552

Santen Pharmaceutical Co., Ltd. Executives & BODs

Santen Pharmaceutical Co., Ltd. Executives & BODs
# Name Age
1 Ms. Kaori Itagaki
General Manager of Investor Relations Group
70
2 Ms. Nobuko Kato
Chief Communications Officer
70
3 Mr. Satoshi Suzuki
Senior Corporate Officer & Head of Corporate Development Division & Director
70
4 Mr. Takahiro Morita
Global Head of Core Principle & Sustainability and Corporate Officer
70
5 Ms. Mika Masunari
General Counsel & Chief Compliance Officer
70
6 Mr. Takeshi Ito
President, Chief Executive Officer & Representative Director
70
7 Mr. Kazuo Koshiji
Chief Financial Officer & Corporate Officer
70
8 Ms. Rie Nakajima
Chief Operating Officer, Corporate Officer & Director
70
9 Mr. Shinichi Teramachi
Corporation Officer, Head of Sales and Head of Japan Sales & Marketing
70
10 Mr. Kenji Morishima
Corporate Officer & Head of China Product Development Department
70

Santen Pharmaceutical Co., Ltd. Competitors

GSK plc Logo
GSK plc

GLAXF

(1.8)
Grifols, S.A. Logo
Grifols, S.A.

GRFS

(0.5)
Pfizer Inc. Logo
Pfizer Inc.

PFE

(2.5)